{"id":"NCT03697811","sponsor":"Santen Inc.","briefTitle":"DE-117 Spectrum 5 Study","officialTitle":"An Open-Label, Multicenter Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution 0.002% in Latanoprost Low/Non-Responder Subjects Diagnosed With Primary Open-Angle Glaucoma or Ocular Hypertension - Spectrum 5 Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-09-27","primaryCompletion":"2022-01-13","completion":"2022-01-13","firstPosted":"2018-10-05","resultsPosted":"2023-08-30","lastUpdate":"2023-08-30"},"enrollment":107,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Open-angle Glaucoma and Ocular Hypertension"],"interventions":[{"type":"DRUG","name":"DE-117 Ophthalmic Solution","otherNames":[]}],"arms":[{"label":"DE-117 Ophthalmic Solution 0.002%","type":"EXPERIMENTAL"}],"summary":"Santen will evaluate the intraocular pressure (IOP) lowering effect and efficacy of DE-117 ophthalmic solution 0.002% in latanoprost low/non-responder subjects diagnosed with POAG or OHT","primaryOutcome":{"measure":"Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) at Month 3.","timeFrame":"Month 3","effectByArm":[{"arm":"DE-117 Ophthalmic Solution 0.002%","deltaMin":-2.96,"sd":2.831}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":7},"locations":{"siteCount":32,"countries":["United States"]},"refs":{"pmids":["37853676"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":107},"commonTop":["Conjunctival hyperaemia","Punctate keratitis","Eye pain","Anterior chamber cell","Conjunctival oedema"]}}